86 Participants Needed

DYNE-251 for Duchenne Muscular Dystrophy

(DELIVER Trial)

Recruiting at 34 trial locations
DC
Overseen ByDyne Clinical Trials
Age: < 18
Sex: Male
Trial Phase: Phase 1 & 2
Sponsor: Dyne Therapeutics
Must be taking: Glucocorticoids
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

Will I have to stop taking my current medications?

The trial requires participants to stay on a stable dose of glucocorticoids (a type of steroid medication) for at least 12 weeks before starting the study and to maintain this stable dose during certain periods of the study. If you are taking eteplirsen or similar exon-skipping therapies, you must stop them at least 12 weeks before joining the trial.

What is the purpose of this trial?

This trial tests DYNE-251, an IV drug, in people with Duchenne muscular dystrophy who can benefit from exon 51 skipping. The drug aims to help their muscles by increasing the dystrophin protein. It works by skipping a faulty part of their gene to produce more of this important protein. Eteplirsen (Exondys 51) was the first drug approved for exon 51 skipping in Duchenne muscular dystrophy.

Eligibility Criteria

Boys aged 4-16 with Duchenne muscular dystrophy (DMD) that can be treated by skipping exon 51, able to undergo muscle biopsy. They must have been on stable glucocorticoids for at least 12 weeks and have a healthy heart function. Non-ambulatory participants should not have lost mobility for more than two years.

Inclusion Criteria

I am between 4 and 16 years old.
A muscle in my arm can be safely biopsied.
I can lift my arms above my head without help.
See 4 more

Exclusion Criteria

I have received gene therapy before.
I haven't taken any experimental drugs that don't target gene skipping in the last 4 months.
I do not have uncontrolled symptoms of heart failure.
See 5 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Multiple-Ascending Dose (MAD) / Placebo-Controlled Period

Participants receive either DYNE-251 or placebo every 4 or 8 weeks to assess safety, tolerability, and dystrophin protein levels

24 weeks
6 visits (in-person) or 3 visits (in-person) depending on dosing schedule

Open-Label Period

Participants receive DYNE-251 every 4 or 8 weeks to further assess safety and efficacy

24 weeks
6 visits (in-person) or 3 visits (in-person) depending on dosing schedule

Long-Term Extension (LTE) Period

Participants continue to receive DYNE-251 every 4 or 8 weeks for long-term safety and efficacy assessment

192 weeks
48 visits (in-person) or 24 visits (in-person) depending on dosing schedule

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

  • DYNE-251
  • Placebo
Trial Overview The trial is testing DYNE-251's effects on safety, tolerability, and muscle protein levels in DMD patients compared to a placebo over multiple stages: an initial controlled phase of 24 weeks, followed by an open-label period of the same duration and then a long-term extension for up to 96 weeks.
Participant Groups
3Treatment groups
Experimental Treatment
Group I: Placebo-Controlled MAD Period - PlaceboExperimental Treatment1 Intervention
Placebo will be administered Q4W or Q8W over 24 weeks.
Group II: Placebo-Controlled MAD Period - DYNE-251Experimental Treatment1 Intervention
DYNE-251 will be administered once every 4 weeks (Q4W) or once every 8 weeks (Q8W) over 24 weeks.
Group III: Open-Label and Long-Term Extension Period - DYNE-251Experimental Treatment1 Intervention
DYNE-251 will be administered Q4W or Q8W for up to 192 weeks after participants complete the Placebo-Controlled MAD Period of the study.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Dyne Therapeutics

Lead Sponsor

Trials
3
Recruited
640+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security